check_circleStudy Completed
Tumors harboring NTRK fusion
Bayer Identifier:
20366
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Expanded access to provide larotrectinib for the treatment of cancers with a NTRK gene fusion
Trial purpose
Larotrectinib expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion, who are ineligible for an ongoing larotrectinib clinical trial or have other considerations that prevent access to larotrectinib through an existing clinical trial. Gene fusion occurs when a gene is made by joining parts of two different genes. NTRK gene fusion can lead to the development of solid tumors in a variety of tissue types. The study drug larotrectinib blocks the action of the NTRK gene fusion.
Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion who are unresponsive to current standard treatment for their condition and also are unable to participate in ongoing clinical trials.
Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion who are unresponsive to current standard treatment for their condition and also are unable to participate in ongoing clinical trials.
Key Participants Requirements
Sex
AllAge
NaN - N/ATrial summary
Enrollment Goal
11Trial Dates
null - TodayPhase
N/ACould I Receive a placebo
NoProducts
Vitrakvi (Larotrectinib, BAY2757556)Accepts Healthy Volunteer
NoTrial design
Trial Type
Expanded AccessIntervention Type
DrugTrial Purpose
TreatmentAllocation
N/ABlinding
N/AAssignment
Single Group AssignmentTrial Arms
1